Methylprednisolone Dosing for Aspiration Pneumonitis

Initial Assessment and Treatment

The diagnosis of aspiration pneumonitis should be confirmed through clinical presentation, history of aspiration risk, and radiographic findings, as recommended by the Infectious Diseases Society of America 1
Sputum cultures or endotracheal aspirates should be obtained to guide antibiotic therapy, according to the Infectious Diseases Society of America 2
For hospitalized patients from home, antibiotic coverage with oral or IV β-lactam/β-lactamase inhibitor, clindamycin, or IV cephalosporin + oral metronidazole is recommended, as suggested by the Infectious Diseases Society of America 1
For ICU patients or those admitted from nursing homes, antibiotic coverage with clindamycin + cephalosporin is recommended, as suggested by the Infectious Diseases Society of America 1

For non-responding patients, consideration of full reinvestigation and potential adjustment of antimicrobial therapy is recommended, according to the Infectious Diseases Society of America 2
Monitoring for common side effects of methylprednisolone, including hyperglycemia, sleep disturbances, and increased risk of infection, is necessary, as noted by the European Crohn's and Colitis Organisation 3

Early initiation of methylprednisolone treatment (<72 hours) is associated with better outcomes, as reported by the European Crohn's and Colitis Organisation 3
Prophylactic measures for patients on corticosteroids, including proton pump inhibitor therapy for GI prophylaxis, should be considered, as recommended by the Society for Immunotherapy of Cancer 4
Consideration of prophylactic antibiotics for pneumocystis pneumonia for patients receiving prolonged steroid therapy is necessary, as recommended by the Society for Immunotherapy of Cancer 4
Low-molecular weight heparin prophylaxis for hospitalized patients on high-dose steroids to prevent venous thromboembolism is recommended, as suggested by the European Crohn's and Colitis Organisation 3

For patients with risk factors for Pseudomonas aeruginosa, adjustment of antibiotic coverage is necessary, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 5